TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Prospective, Double-Blind Placebo Controlled Study of Oral Ergocalciferol in the Treatment of Pruritis in Hemodialysis Patients
Brief Summary: Pruritis (itching) is common in many people with chronic renal failure on hemodialysis. There may be many different reasons for the pruritis. Efforts to treat the problem have not been very effective.

Vitamin D levels have been found to be low in many hemodialysis patients. Since vitamin D plays an important role in the skin and is effective in treatment of certain skin conditions that involve pruritis, it may have a role in treatment of pruritis in hemodialysis patients.

The objective of the investigators study is to determine the effect of supplementation with oral vitamin D2 (ergocalciferol) on pruritis in hemodialysis patients.


Options:
A: Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): N/A
B: Arm Label: CR845 0.5mcg/kg; Type: ACTIVE_COMPARATOR; Interventions: Drug: CR845 0.5 mcg/kg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CR845 0.5 mcg/kg; Assigned to Arm(s): CR845 0.5mcg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: MT-9938 2.5μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nalfurafine hydrochloride(MT-9938) 2.5μg | Arm Label: MT-9938 5μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nalfurafine hydrochloride(MT-9938) 5μg | Arm Label: MT-9938 10μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nalfurafine hydrochloride(MT-9938) 10μg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Nalfurafine hydrochloride(MT-9938) 2.5μg; Assigned to Arm(s): MT-9938 2.5μg | Intervention Type: DRUG; Name: Nalfurafine hydrochloride(MT-9938) 5μg; Assigned to Arm(s): MT-9938 5μg | Intervention Type: DRUG; Name: Nalfurafine hydrochloride(MT-9938) 10μg; Assigned to Arm(s): MT-9938 10μg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Ergocalciferol; Type: ACTIVE_COMPARATOR; Interventions: Drug: 50,000 Units Ergocalciferol | Arm Label: oral placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 50,000 Units Ergocalciferol; Assigned to Arm(s): Ergocalciferol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): oral placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Helping Problem Drinkers on the Internet
Brief Summary: The main aim of this study is to compare the impact of a minimal and a full Internet-based self-help intervention for problem drinkers in the general population.


Options:
A: Intervention Type: BEHAVIORAL; Name: Check Your Drinking (CYD); Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Alcohol Help Centre (AHC); Assigned to Arm(s): N/A
B: Arm Label: Alcohol education and prevention; Type: EXPERIMENTAL; Interventions: Behavioral: AlcoholEdu for College | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: AlcoholEdu for College; Assigned to Arm(s): Alcohol education and prevention
C: Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Training & support (T&S); Type: EXPERIMENTAL; Interventions: Other: Training and support (T&S) | Arm Label: Financial incentive; Type: EXPERIMENTAL; Interventions: Other: Financial incentive | Arm Label: E-SBI; Type: EXPERIMENTAL; Interventions: Other: E-SBI (online screening and brief intervention) | Arm Label: T&S and financial incentive; Type: EXPERIMENTAL; Interventions: Other: Training and support (T&S), Other: Financial incentive | Arm Label: T&S and e-SBI; Type: EXPERIMENTAL; Interventions: Other: Training and support (T&S), Other: E-SBI (online screening and brief intervention) | Arm Label: Financial incentive and e-SBI; Type: EXPERIMENTAL; Interventions: Other: Financial incentive, Other: E-SBI (online screening and brief intervention) | Arm Label: T&S, financial incentive and e-SBI; Type: EXPERIMENTAL; Interventions: Other: Training and support (T&S), Other: Financial incentive, Other: E-SBI (online screening and brief intervention) | Intervention Type: OTHER; Name: Training and support (T&S); Assigned to Arm(s): T&S and e-SBI, T&S and financial incentive, T&S, financial incentive and e-SBI, Training & support (T&S) | Intervention Type: OTHER; Name: Financial incentive; Assigned to Arm(s): Financial incentive, Financial incentive and e-SBI, T&S and financial incentive, T&S, financial incentive and e-SBI | Intervention Type: OTHER; Name: E-SBI (online screening and brief intervention); Assigned to Arm(s): E-SBI, Financial incentive and e-SBI, T&S and e-SBI, T&S, financial incentive and e-SBI
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Check Your Drinking University version | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Check Your Drinking University version; Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Second-line Treatment of Post-partum Haemorrhage With Intrarectal Misoprostol: a Multicentre, Double Blind, Randomized Placebo-controlled Trial
Brief Summary: Postpartum haemorrhage (PPH) remains the major cause of maternal mortality in France. The most efficient treatment of severe PPH is sulprostone which is associated with cardiac complications. The objective of this study was to assess the efficacy and the safety of intrarectal misoprostol for curative postpartum haemorrhage treatment.

We conducted a multicenter double blind randomized placebo control trial between June 2004 and December 2007, among consenting women with postpartum haemorrhage and failure to oxytocin treatment.

Our main criteria of judgement was quantification of blood loss and the use of sulprostone between the two groups using either misoprostol intrarectal tablets (5X200mg ) or placebo in similar opaque introducer.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: MISOPROSTOL; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): MISOPROSTOL | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Other: Misoprostol + referral | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo + referral | Intervention Type: OTHER; Name: Misoprostol + referral; Assigned to Arm(s): Misoprostol | Intervention Type: OTHER; Name: Placebo + referral; Assigned to Arm(s): Placebo
C: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol, Placebo
D: Arm Label: Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: DECISION+: Une Formation Pour Les médecins de Famille Sur la Prise de décision partagée Afin d'Optimiser Les décisions Cliniques Concernant l'Utilisation d'Antibiotiques Pour Les Infections aiguës Des Voies Respiratoires (IAVR)
Brief Summary: Decisions about the use of antibiotics for acute respiratory infections are the most frequently reported reason for consulting a family physician. Although it varies according to the specific type of acute respiratory infections, the use of antibiotics is estimated to be 63% to 67%, well above the expected prevalence of bacterial infections thus suggesting overuse of antibiotics. Consequently, there is an urgent need for helping family physicians and their patients to improve the clinical decision making process regarding the use of antibiotics for acute respiratory infections. We will evaluate the impact of DECISION +, a multifaceted intervention program that includes training in shared decision making, reminders and feedback targeting physicians, and decision support tools targeting patients on the decision to use antibiotics for acute respiratory infections. Results from this study will lay the ground for a national strategy targeting the improvement of the clinical decision making process regarding antibiotic use for acute respiratory infections in primary care. In turn, this will increase quality of care and patient safety.


Options:
A: Arm Label: C-reactive protein test; Type: EXPERIMENTAL; Interventions: Device: C-reactive protein test | Intervention Type: DEVICE; Name: C-reactive protein test; Assigned to Arm(s): C-reactive protein test
B: Arm Label: DECISION+ Program; Type: EXPERIMENTAL; Interventions: Behavioral: Decision+ program (to improve optimal drug prescription for ARI) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Decision+ program (to improve optimal drug prescription for ARI); Assigned to Arm(s): DECISION+ Program
C: Intervention Type: OTHER; Name: laboratory value procalcitonin; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: No antibiotics if se-procalcitonin is below stated limit; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: DECISION+: Une Formation Pour Les médecins de Famille Sur la Prise de décision partagée Afin d'Optimiser Les décisions Cliniques Concernant l'Utilisation d'Antibiotiques Pour Les Infections aiguës Des Voies Respiratoires (IAVR)
Brief Summary: Decisions about the use of antibiotics for acute respiratory infections are the most frequently reported reason for consulting a family physician. Although it varies according to the specific type of acute respiratory infections, the use of antibiotics is estimated to be 63% to 67%, well above the expected prevalence of bacterial infections thus suggesting overuse of antibiotics. Consequently, there is an urgent need for helping family physicians and their patients to improve the clinical decision making process regarding the use of antibiotics for acute respiratory infections. We will evaluate the impact of DECISION +, a multifaceted intervention program that includes training in shared decision making, reminders and feedback targeting physicians, and decision support tools targeting patients on the decision to use antibiotics for acute respiratory infections. Results from this study will lay the ground for a national strategy targeting the improvement of the clinical decision making process regarding antibiotic use for acute respiratory infections in primary care. In turn, this will increase quality of care and patient safety.


Options:
A: Arm Label: Decision aid; Type: ACTIVE_COMPARATOR; Interventions: Other: Decision Aid | Arm Label: Normal care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Decision Aid; Assigned to Arm(s): Decision aid
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Bowel cancer screening decision aid | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: Bowel cancer screening decision aid | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Other: Australian Government Bowel Cancer Screening booklet | Intervention Type: OTHER; Name: Bowel cancer screening decision aid; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Bowel cancer screening decision aid; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Australian Government Bowel Cancer Screening booklet; Assigned to Arm(s): 3
C: Arm Label: DECISION+ Program; Type: EXPERIMENTAL; Interventions: Behavioral: Decision+ program (to improve optimal drug prescription for ARI) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Decision+ program (to improve optimal drug prescription for ARI); Assigned to Arm(s): DECISION+ Program
D: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: MyHealthyChoices | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Health Risk Assessment | Intervention Type: BEHAVIORAL; Name: MyHealthyChoices; Assigned to Arm(s): Intervention Group | Intervention Type: OTHER; Name: Health Risk Assessment; Assigned to Arm(s): Control Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: DECISION+: Une Formation Pour Les médecins de Famille Sur la Prise de décision partagée Afin d'Optimiser Les décisions Cliniques Concernant l'Utilisation d'Antibiotiques Pour Les Infections aiguës Des Voies Respiratoires (IAVR)
Brief Summary: Decisions about the use of antibiotics for acute respiratory infections are the most frequently reported reason for consulting a family physician. Although it varies according to the specific type of acute respiratory infections, the use of antibiotics is estimated to be 63% to 67%, well above the expected prevalence of bacterial infections thus suggesting overuse of antibiotics. Consequently, there is an urgent need for helping family physicians and their patients to improve the clinical decision making process regarding the use of antibiotics for acute respiratory infections. We will evaluate the impact of DECISION +, a multifaceted intervention program that includes training in shared decision making, reminders and feedback targeting physicians, and decision support tools targeting patients on the decision to use antibiotics for acute respiratory infections. Results from this study will lay the ground for a national strategy targeting the improvement of the clinical decision making process regarding antibiotic use for acute respiratory infections in primary care. In turn, this will increase quality of care and patient safety.


Options:
A: Arm Label: Electronic Decision Support; Type: EXPERIMENTAL; Interventions: Behavioral: Decision Support for ARI Management | Arm Label: Paper Decision Support; Type: EXPERIMENTAL; Interventions: Behavioral: Decision Support for ARI Management | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Decision Support for ARI Management; Assigned to Arm(s): Electronic Decision Support, Paper Decision Support
B: Arm Label: DECISION+ Program; Type: EXPERIMENTAL; Interventions: Behavioral: Decision+ program (to improve optimal drug prescription for ARI) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Decision+ program (to improve optimal drug prescription for ARI); Assigned to Arm(s): DECISION+ Program
C: Arm Label: Intervention areas; Type: EXPERIMENTAL; Interventions: Other: Multifaceted information campaign | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Multifaceted information campaign; Assigned to Arm(s): Intervention areas
D: Arm Label: Posted commitment letter; Type: EXPERIMENTAL; Interventions: Other: Posted commitment letter | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Posted commitment letter; Assigned to Arm(s): Posted commitment letter

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: DECISION+: Une Formation Pour Les médecins de Famille Sur la Prise de décision partagée Afin d'Optimiser Les décisions Cliniques Concernant l'Utilisation d'Antibiotiques Pour Les Infections aiguës Des Voies Respiratoires (IAVR)
Brief Summary: Decisions about the use of antibiotics for acute respiratory infections are the most frequently reported reason for consulting a family physician. Although it varies according to the specific type of acute respiratory infections, the use of antibiotics is estimated to be 63% to 67%, well above the expected prevalence of bacterial infections thus suggesting overuse of antibiotics. Consequently, there is an urgent need for helping family physicians and their patients to improve the clinical decision making process regarding the use of antibiotics for acute respiratory infections. We will evaluate the impact of DECISION +, a multifaceted intervention program that includes training in shared decision making, reminders and feedback targeting physicians, and decision support tools targeting patients on the decision to use antibiotics for acute respiratory infections. Results from this study will lay the ground for a national strategy targeting the improvement of the clinical decision making process regarding antibiotic use for acute respiratory infections in primary care. In turn, this will increase quality of care and patient safety.


Options:
A: Intervention Type: DEVICE; Name: Antimicrobial Prescribing Decision Support; Assigned to Arm(s): N/A
B: Arm Label: dosing decision support; Type: EXPERIMENTAL; Interventions: Other: weight based dosing decision support | Arm Label: no decision support; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: weight based dosing decision support; Assigned to Arm(s): dosing decision support
C: Arm Label: Electronic Decision Support; Type: EXPERIMENTAL; Interventions: Behavioral: Decision Support for ARI Management | Arm Label: Paper Decision Support; Type: EXPERIMENTAL; Interventions: Behavioral: Decision Support for ARI Management | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Decision Support for ARI Management; Assigned to Arm(s): Electronic Decision Support, Paper Decision Support
D: Arm Label: DECISION+ Program; Type: EXPERIMENTAL; Interventions: Behavioral: Decision+ program (to improve optimal drug prescription for ARI) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Decision+ program (to improve optimal drug prescription for ARI); Assigned to Arm(s): DECISION+ Program

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Letrozole and Berberine in Infertile PCOS Patients
Brief Summary: Polycystic ovary syndrome (PCOS) is a heterogeneous disorder affecting almost4%-7% of the female population of reproductive age. Its heterogeneity is characterized by a wide spectrum of features, including ovulatory dysfunction and infertility, hyperandrogenism, hyperinsulinemia, insulin resistance (IR), and progression to type 2 diabetes.Since the Ming Dynasty in China,PCOS has been defined as "phlegm and wetness"infertility in traditional Chinese medicine ,namely "metabolic infertility".Chinese herbs have been used to treat PCOS for thousands of years with good effects.Berberine has also been used for diabetic patients in traditional Chinese medicine for hundreds of years. Recent studies have reported its effects on hyperglycemia and dyslipidemia.The purpose of this study is to determine whether Letrozole combined with berberine are effective in the treatment of infertile PCOS patients.


Options:
A: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: HCG | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Drug: HCG | Arm Label: Group 3; Type: EXPERIMENTAL; Interventions: Drug: HCG | Arm Label: Group 4; Type: EXPERIMENTAL; Interventions: Drug: HCG | Intervention Type: DRUG; Name: HCG; Assigned to Arm(s): Group 1, Group 2, Group 3, Group 4
B: Arm Label: Crispbread; Type: EXPERIMENTAL; Interventions: Behavioral: Crispbread | Arm Label: Liquid meal replacement; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Crispbread | Intervention Type: BEHAVIORAL; Name: Crispbread; Assigned to Arm(s): Crispbread, Liquid meal replacement
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clomiphene citrate | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Letrozole | Intervention Type: DRUG; Name: Clomiphene citrate; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Letrozole; Assigned to Arm(s): B
D: Arm Label: Letrozole -Berberine; Type: EXPERIMENTAL; Interventions: Drug: Letrozole -Berberine | Arm Label: Letrozole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Letrozole | Arm Label: Berberine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Berberine | Intervention Type: DRUG; Name: Letrozole -Berberine; Assigned to Arm(s): Letrozole -Berberine | Intervention Type: DRUG; Name: Letrozole; Assigned to Arm(s): Letrozole | Intervention Type: DRUG; Name: Berberine; Assigned to Arm(s): Berberine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Letrozole and Berberine in Infertile PCOS Patients
Brief Summary: Polycystic ovary syndrome (PCOS) is a heterogeneous disorder affecting almost4%-7% of the female population of reproductive age. Its heterogeneity is characterized by a wide spectrum of features, including ovulatory dysfunction and infertility, hyperandrogenism, hyperinsulinemia, insulin resistance (IR), and progression to type 2 diabetes.Since the Ming Dynasty in China,PCOS has been defined as "phlegm and wetness"infertility in traditional Chinese medicine ,namely "metabolic infertility".Chinese herbs have been used to treat PCOS for thousands of years with good effects.Berberine has also been used for diabetic patients in traditional Chinese medicine for hundreds of years. Recent studies have reported its effects on hyperglycemia and dyslipidemia.The purpose of this study is to determine whether Letrozole combined with berberine are effective in the treatment of infertile PCOS patients.


Options:
A: Arm Label: Letrozole -Berberine; Type: EXPERIMENTAL; Interventions: Drug: Letrozole -Berberine | Arm Label: Letrozole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Letrozole | Arm Label: Berberine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Berberine | Intervention Type: DRUG; Name: Letrozole -Berberine; Assigned to Arm(s): Letrozole -Berberine | Intervention Type: DRUG; Name: Letrozole; Assigned to Arm(s): Letrozole | Intervention Type: DRUG; Name: Berberine; Assigned to Arm(s): Berberine
B: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: HCG | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Drug: HCG | Arm Label: Group 3; Type: EXPERIMENTAL; Interventions: Drug: HCG | Arm Label: Group 4; Type: EXPERIMENTAL; Interventions: Drug: HCG | Intervention Type: DRUG; Name: HCG; Assigned to Arm(s): Group 1, Group 2, Group 3, Group 4
C: Arm Label: Berberine; Type: EXPERIMENTAL; Interventions: Drug: Berberine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Berberine; Assigned to Arm(s): Berberine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clomiphene citrate | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Letrozole | Intervention Type: DRUG; Name: Clomiphene citrate; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Letrozole; Assigned to Arm(s): B

Answer: A